The product is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis, Lupin said in a statement.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3a5bqwm
via IFTTT
Home »
Healthcare/Biotech-Industry-Economic Times
» Lupin gets USFDA nod to market generic Sevelamer Carbonate tablets
0 comments:
Post a Comment